Fundz

Amani Therapeutics announced it raised $35 Million in an initial filing from an offering of $60 Million

PRIVATEOct 01, 2026

Amount Raised

$35 Million

Round Type

Venture

BiotechnologyHealth CareTherapeutics

Company Information

Company

Amani Therapeutics

About

Amani Therapeutics is a biotechnology company dedicated to developing highly efficacious, safer medicines for people living with serious neuropsychiatric disorders. The company focuses on AM-01, a potential best-in-class therapy for schizophrenia, which combines clozapine with a novel chemical entity. Their goal is to improve treatment safety and efficacy for patients who are often underserved by existing therapies.

Fundz sees it the moment Amani Therapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Predictive Intelligence
Strategic

ML-powered predictions for Amani Therapeutics's next move

See what Strategic adds

Amani Therapeutics raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.